Table 1.
Cases (n = 41) | Controls (n = 111) | P-value | |
---|---|---|---|
Age (years), med (IQR) | 44 (33, 49) | 37 (30, 43) | 0.04 |
Female, n (%) | 14 (34) | 13 (12) | 0.003 |
Race/Ethnicity, n (%) | 0.25 | ||
White | 21 (51) | 46 (41) | |
Black | 9 (22) | 42 (38) | |
Hispanic | 9 (22) | 21 (19) | |
Other | 2 (5) | 2 (2) | |
Hepatitis C Seropositive, n (%)§ | 2 (9) | 9 (12) | |
Study Week (Time to a new AIDS-defining event or death after HAART-initiation), med (IQR) | 12 (5, 53) | – | |
Baseline values: med (IQR) | |||
CD4 cells, per mm3 | 42 (17, 176) | 62 (20, 222) | 0.32 |
HIV-RNA, log10 copies/mL | 5.51 (4.88, 6.02) | 5.40 (4.67, 6.04) | 0.75 |
Hemoglobin, Gm/dL | 11.9 (10.4, 13.7) | 12.0 (11.9, 13.8) | 0.01 |
%CD8+/HLA-DR+/CD38+ | 56 (44, 63) | 50 (40, 62) | 0.08 |
sTNFR-I, pg/mL | 1423(1215, 1789) | 1175 (902, 1487) | 0.001 |
sTNFR-II, ng/mL | 8.42(6.72, 12.9) | 7.47(4.85, 10.33) | 0.06 |
sCD27, U/mL | 420 (304, 653) | 304 (230, 448) | 0.007 |
sCD40L, ng/mL | 0.72 (0.36, 1.13) | 0.52 (0.24, 0.93) | 0.14 |
sTRAIL, pg/mL | 449 (309, 639) | 504 (349, 715) | 0.31 |
IL-6, pg/mL | 3.13 (1.77, 4.78) | 1.48 (1.02, 3.10) | 0.002 |
Time updated values at the onset of an AIDS defining illness or death, med (IQR) | |||
CD4 cell count, per mm3 | 66 (17, 236) | 145 (25, 366) | 0.07 |
HIV-RNA, log10 cop/mL | 2.89 (1.69, 5.67) | 2.58 (1.69, 5.37) | 0.39 |
HIV-RNA < 200 cop/mL, n (%) | 50 (45) | 18 (44) | 1.0 |
HIV-RNA < 50 cop/mL, n (%) | 12 (29) | 40 (36) | 0.56 |
%CD8+/HLA-DR+/CD38+ | 44 (36, 57) | 39 (25, 52) | 0.07 |
Time-updated values among cases indicate the latest, antecedent values before a clinical event; for control subjects values from the same study week, or the closest antecedent study week to that of their corresponding case were used. The significance of differences between cases and controls are indicated by:
=p<0.001;
=p<0.05 and p ≥ 0.001;
= p < 0.10 and p ≥ 0.05.
HCV-serostatus was available in 23 cases and 75 controls.